Ulixertinib hydrochloride
Cat. No.: IBDI-435294
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.
Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution
Online Inquiry
Product Details
| Target |
ERK |
| Molecular Weight |
469.79 |
| Appearance |
Solid |
| Synonyms |
BVD-523 hydrochloride, VRT752271 hydrochloride |
| Purity |
99.89% |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
